JO3658B1 - بروتينات اندماج - Google Patents

بروتينات اندماج

Info

Publication number
JO3658B1
JO3658B1 JOP/2016/0076A JOP20160076A JO3658B1 JO 3658 B1 JO3658 B1 JO 3658B1 JO P20160076 A JOP20160076 A JO P20160076A JO 3658 B1 JO3658 B1 JO 3658B1
Authority
JO
Jordan
Prior art keywords
fusion proteins
present
time
extended
diabetes
Prior art date
Application number
JOP/2016/0076A
Other languages
English (en)
Inventor
Bruce Baldwin David
Duane Dickinson Craig
Alan Lazar Gregory
Wesley Day Johnathan
Ihor Korytko Andrew
Michael Beals John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3658(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3658B1 publication Critical patent/JO3658B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات اندماج تشتمل على مساعد مستقبل إنسولين مدمج مع منطقة<span dir="LTR">Fc </span> <span dir="LTR">IgG</span> بشرية من خلال استخدام رابط ببتيد، واستخدام بروتينات الاندماج المذكورة في معالجة مرض السكري. يكون لبروتينات الاندماج للاختراع الحالي خاصية ممتدة المفعول وتكون نافعة في توفير تحكم في مستوى الجلوكوز القاعدة لفترة زمنية ممتدة<span dir="LTR">.</span>
JOP/2016/0076A 2015-05-07 2016-04-21 بروتينات اندماج JO3658B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07

Publications (1)

Publication Number Publication Date
JO3658B1 true JO3658B1 (ar) 2020-08-27

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0076A JO3658B1 (ar) 2015-05-07 2016-04-21 بروتينات اندماج

Country Status (42)

Country Link
US (4) US9855318B2 (ar)
EP (1) EP3292141B1 (ar)
JP (1) JP6591562B2 (ar)
KR (1) KR102059736B1 (ar)
CN (1) CN107531806B (ar)
AR (1) AR105616A1 (ar)
AU (1) AU2016257659B2 (ar)
BR (1) BR112017020502A2 (ar)
CA (1) CA2981102A1 (ar)
CL (1) CL2017002761A1 (ar)
CO (1) CO2017011301A2 (ar)
CR (1) CR20170469A (ar)
CY (1) CY1122929T1 (ar)
DK (1) DK3292141T3 (ar)
DO (1) DOP2017000258A (ar)
EA (1) EA039770B1 (ar)
EC (1) ECSP17073650A (ar)
ES (1) ES2799099T3 (ar)
HK (1) HK1244019A1 (ar)
HR (1) HRP20200503T1 (ar)
IL (1) IL254965B (ar)
JO (1) JO3658B1 (ar)
LT (1) LT3292141T (ar)
MA (1) MA42037B1 (ar)
MD (1) MD3292141T2 (ar)
ME (1) ME03709B (ar)
MX (1) MX2017014284A (ar)
MY (1) MY183025A (ar)
NZ (1) NZ736470A (ar)
PE (1) PE20180507A1 (ar)
PH (1) PH12017502025B1 (ar)
PL (1) PL3292141T3 (ar)
PT (1) PT3292141T (ar)
RS (1) RS60044B1 (ar)
SG (1) SG11201708194WA (ar)
SI (1) SI3292141T1 (ar)
SV (1) SV2017005548A (ar)
TN (1) TN2018000059A1 (ar)
TW (1) TWI656132B (ar)
UA (1) UA122146C2 (ar)
WO (1) WO2016178905A1 (ar)
ZA (1) ZA201706334B (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP6862546B2 (ja) 2016-07-27 2021-04-21 ヒューレット−パッカード デベロップメント カンパニー エル．ピー．Ｈｅｗｌｅｔｔ‐Ｐａｃｋａｒｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ， Ｌ．Ｐ． デジタル液体レベルセンサを有する流体供給カートリッジ用の水平方向インターフェース
HUE055417T2 (hu) * 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR20200125590A (ko) * 2018-01-26 2020-11-04 제넨테크, 인크. 조성물 및 사용 방법
MX2020014027A (es) 2018-06-25 2021-03-09 Univ Washington Dise?o de novo de mimeticos de interleucina potentes y selectivos.
US11267862B2 (en) * 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3892628B1 (en) * 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
JP2022502467A (ja) 2018-10-10 2022-01-11 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−ｆｃコンジュゲートおよびそれらの医学的使用
WO2020106708A1 (en) 2018-11-20 2020-05-28 University Of Washington Split interleukin mimetics and their use
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
FI4073098T3 (fi) * 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides
CA3173628A1 (en) 2020-04-07 2021-10-14 Thomas Linsky De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
HRP20230990T1 (hr) 2020-04-10 2023-12-08 Akston Biosciences Corporation Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
AU2021401635A1 (en) 2020-12-14 2023-06-22 Eli Lilly And Company Methods of treating diabetes
EP4373861A2 (en) 2021-07-23 2024-05-29 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
WO2023174370A1 (zh) * 2022-03-16 2023-09-21 北京拓界生物医药科技有限公司 人胰岛素类似物、其融合蛋白及医药用途
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物
WO2023247640A1 (en) 2022-06-23 2023-12-28 Sanofi Single chain insulins and fc conjugates thereof
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
JP4629047B2 (ja) * 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
AU2003296244A1 (en) 2003-10-02 2005-05-11 Carl Zeiss Smt Ag Optical subassembly and projection objective for semiconductor lithography
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
EP3173484B1 (en) * 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) * 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
US9636420B2 (en) 2008-07-23 2017-05-02 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2012109429A2 (en) 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
MX2015005662A (es) 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
PT2963055T (pt) 2013-02-26 2019-07-25 Hanmi Pharm Ind Co Ltd Conugado de insulina específico ao local
KR20150127596A (ko) * 2013-03-14 2015-11-17 리제너론 파아마슈티컬스, 인크. 아펠린 융합 단백질 및 이들의 용도
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
AU2015349890B2 (en) 2014-11-21 2018-08-30 Merck Sharp & Dohme Llc Insulin receptor partial agonists
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
US20200390865A1 (en) 2020-12-17
NZ736470A (en) 2019-04-26
CA2981102A1 (en) 2016-11-10
DK3292141T3 (da) 2020-04-20
KR20170134614A (ko) 2017-12-06
US10709766B2 (en) 2020-07-14
PH12017502025A1 (en) 2018-04-02
TW201712029A (zh) 2017-04-01
MD3292141T2 (ro) 2020-07-31
AU2016257659A1 (en) 2017-10-12
CR20170469A (es) 2017-11-14
UA122146C2 (uk) 2020-09-25
EP3292141B1 (en) 2020-02-12
US20160324932A1 (en) 2016-11-10
ECSP17073650A (es) 2018-02-28
TWI656132B (zh) 2019-04-11
US20220211818A1 (en) 2022-07-07
PL3292141T3 (pl) 2020-06-29
CL2017002761A1 (es) 2018-05-18
MA42037B1 (fr) 2020-03-31
PT3292141T (pt) 2020-04-22
SG11201708194WA (en) 2017-11-29
AR105616A1 (es) 2017-10-25
JP2018515088A (ja) 2018-06-14
EA201792199A1 (ru) 2018-03-30
CY1122929T1 (el) 2021-10-29
MY183025A (en) 2021-02-07
DOP2017000258A (es) 2017-12-31
CN107531806A (zh) 2018-01-02
PH12017502025B1 (en) 2018-04-02
EA039770B1 (ru) 2022-03-11
JP6591562B2 (ja) 2019-10-16
HK1244019A1 (zh) 2018-07-27
HRP20200503T1 (hr) 2020-06-26
TN2018000059A1 (en) 2019-07-08
KR102059736B1 (ko) 2019-12-26
SI3292141T1 (sl) 2020-04-30
EP3292141A1 (en) 2018-03-14
ME03709B (me) 2021-01-20
PE20180507A1 (es) 2018-03-09
US11253574B2 (en) 2022-02-22
AU2016257659B2 (en) 2018-08-09
US20180177851A1 (en) 2018-06-28
US9855318B2 (en) 2018-01-02
ZA201706334B (en) 2020-01-29
CN107531806B (zh) 2022-06-07
RS60044B1 (sr) 2020-04-30
MX2017014284A (es) 2018-03-23
ES2799099T3 (es) 2020-12-14
IL254965B (en) 2021-03-25
WO2016178905A1 (en) 2016-11-10
LT3292141T (lt) 2020-03-25
SV2017005548A (es) 2018-04-24
US12059452B2 (en) 2024-08-13
BR112017020502A2 (pt) 2018-07-03
CO2017011301A2 (es) 2018-03-20
IL254965A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
PH12017502025B1 (en) Fusion proteins
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
IL267406A (en) Combined treatment of specific antibodies against cd20/cd3 and agonists of 4-1bb (cd137)
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
MX2016014647A (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
NZ760789A (en) Uti fusion proteins
PT3257524T (pt) Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение